Status:
COMPLETED
Screening Protocol for Genetic Diseases of Allergic Inflammation
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)
Conditions:
Eosinophilic Disease
Immune Deficiency
Eligibility:
All Genders
1-99 years
Brief Summary
Background: * Mast cells are responsible for most symptoms of allergic reactions. In some allergic diseases, it is unusually easy to cause mast cells to release their contents and cause allergic reac...
Detailed Description
This protocol is designed to screen subjects (and some family members) with suspected or identified genetic diseases of allergic inflammation or mast cell homeostasis and activation. Patients determin...
Eligibility Criteria
Inclusion
- INCLUSION CRITERIA:
- Subjects, ages birth to 99 years old, known to have or suspected of having an inherited or acquired genetic disorder resulting in severe allergic inflammation and/or reactivity associated with alterations in mast cell and/or eosinophil homeostasis or activation, will be eligible for enrollment. Because of the intensive time and labor required for research laboratory testing, subjects will be enrolled only if in the opinion of the investigator (based on discussions with the patient s private physician) there is a high index of suspicion of a genetic basis for the observed allergic manifestation(s).
- Blood relatives of enrolled subjects will be eligible for enrollment.
- There will be no discrimination as to age, gender, race, or disability.
- Subjects must have a health care provider outside of the NIH.
- Subjects must agree to have their blood stored for future studies of the immune system and/or other medical conditions.
- EXCLUSION CRITERIA:
- \- Ongoing systemic immune modulation with agents such as biologics that target mast cells and eosinophils, immune modulating or cytotoxic chemotherapy, and/or malignancy may be grounds for possible exclusion if, in the opinion of the investigator, the presence of such a disease process would interfere with evaluation.
Exclusion
Key Trial Info
Start Date :
November 2 2010
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
Estimated Enrollment :
824 Patients enrolled
Trial Details
Trial ID
NCT00852943
Start Date
November 2 2010
Last Update
January 9 2026
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
National Institutes of Health Clinical Center
Bethesda, Maryland, United States, 20892